{"schema":"sb.node.v1","id":"sb:e/85a46c3fe31041288a0a56c9","kind":"entity","label":{"text":"eli lilly","locale":"en"},"identity":{"anchor":"label:en:eli lilly","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-29T23:27:11.436223+00:00","releaseId":"sb-5278fe97455c","snapshot":"deploy 4eb44af96aa019751c00666e75064bc109388622"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":448,"separatePublishers":131,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.301,"named":135,"of":448,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn only from rows whose own title or URL names the subject (the entity graph's subject gate)","blind":["only 30% of the 448 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"canonical","kind":"legacy","kindBasis":"seed","reason":"entity graph provenance 'curated'; part of the hand-written seed vocabulary that predates machine promotion; no receipt exists","policy":"promotion (seed vocabulary; no receipt)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-05-06","to":"2026-10-30","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.056: about 94% of mentions carry no typed assertion"]}},"dimensions":{"domains":["biotech_pharma"],"activeDays":63,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/ccb9be4a460a270313bc4ce9","kind":"observation","label":"Bitcoin News · 2026-10-29 · Walmart, Eli Lilly Among Latest Objectors to OKXICE Tokenized Stocks Platform","url":"https://news.bitcoin.com/finance/walmart-eli-lilly-growing-pushback-okxice-tokenized-stocks-platform/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/7aa692e4d03affaa8eadf22c","kind":"observation","label":"Endpoints News · 2026-10-29 · Lilly again far surpasses revenue expectations","url":"https://endpoints.news/lilly-again-far-surpasses-revenue-expectations/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/ced18955a1bcf48ba318c055","kind":"observation","label":"an unnamed outlet · 2026-10-29 · Healthcare's AI race heats up","url":"https://www.businessinsider.com/retatrutide-ozempic-eli-lilly-health-tech-ai-robin-ro-medicine","match":{"surface":"url","basis":"admitted by the entity graph's subject gate (title or URL); the headline does not name the subject by the door's on-topic test, the URL path does"}},{"id":"sb:o/05b7cafe81f43e2b0d4efdf5","kind":"observation","label":"STAT News · 2026-10-28 · STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more","url":"https://www.statnews.com/pharmalot/2026/10/28/battles-over-340b-lilly-reports-weight-loss-drug-results/?utm_campaign=rss","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/95e6fca0b9b91563860f342c","kind":"observation","label":"STAT News · 2026-10-28 · STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study","url":"https://www.statnews.com/2026/10/28/biotech-news-lillys-triple-g-drug-beats-ozempic-in-head-to-head-study/?utm_campaign=rss","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/e77e97764017358f46af38e1","kind":"observation","label":"STAT News · 2026-10-28 · STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study","url":"https://www.statnews.com/2026/10/28/retatrutide-vs-ozempic-lilly-diabetes-study/?utm_campaign=rss","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/a6a47f93decc7f28005c20e1","kind":"observation","label":"Psychedelic Alpha · 2026-10-28 · Pharma Moves In: Investors, Developers and Lilly’s Carole Ho at the Psychedelic Healthcare Forum","url":"https://psychedelicalpha.com/news/pharma-moves-in-investors-developers-and-lillys-carole-ho-at-the-psychedelic-healthcare-forum/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/1b3991056e0bba9c6bdcc091","kind":"observation","label":"Clinical Trials Arena · 2026-10-28 · Lilly’s retatrutide beats Ozempic in head-to-head trial","url":"https://www.clinicaltrialsarena.com/news/lillys-retatrutide-beats-ozempic-in-head-to-head-trial/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/2c44fff90693537bad8c887e","kind":"observation","label":"Endpoints News · 2026-10-28 · Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes","url":"https://endpoints.news/lillys-triple-g-drug-retatrutide-outshines-novos-ozempic-in-diabetes/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/799af0d3ebe89f518a09ab05","kind":"observation","label":"an unnamed outlet · 2026-10-28 · Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss","url":"https://www.businessinsider.com/retatrutide-ozempic-weight-loss-comparison-side-effects-eli-lilly-results-2026-10","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}}],"cursor":"c1.eyJpZCI6InNiOmUvODVhNDZjM2ZlMzEwNDEyODhhMGE1NmM5IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTI5VDIzOjI3OjExLjQzNjIyMyswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity whose own title or URL (the entity graph's subject gate) names it; each says which in match. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":12,"byKind":{"claim":2,"co-mentioned":10},"items":[{"id":"sb:p/fe4eeaa58121cb970e760687","kind":"claim","label":"Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss — corroborated","role":"named-in","relationKind":"claim","members":1},{"id":"sb:p/23edc8258ddcf0e67305bf57","kind":"claim","label":"New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer — single source","role":"named-in","relationKind":"claim","members":1},{"kind":"relation","label":"co-mentioned with glp-1 (134 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/780e192cbb11a0ba2d140505"},{"kind":"relation","label":"co-mentioned with ai (127 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9c21ab461cbc4a7940c5b532"},{"kind":"relation","label":"co-mentioned with fda (124 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/71324105fbda62f5fde99cb9"},{"kind":"relation","label":"co-mentioned with weight loss (85 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/44154c438d0539a66f332000"},{"kind":"relation","label":"co-mentioned with novo nordisk (79 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/73e95c35dd32f4410d3327d7"},{"kind":"relation","label":"co-mentioned with united states (69 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ac3f5a7f6581ed3ea89e5e52"},{"kind":"relation","label":"co-mentioned with china (66 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4b144d3ab70932c3528bd6d1"},{"kind":"relation","label":"co-mentioned with buy (57 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e6a7133034049ff4b4799676"}],"cursor":"c1.eyJpZCI6InNiOmUvODVhNDZjM2ZlMzEwNDEyODhhMGE1NmM5IiwibCI6InJlbGF0aW9ucyIsIm8iOjEwLCJrIjpudWxsLCJhIjoiMjAyNi0xMC0yOVQyMzoyNzoxMS40MzYyMjMrMDA6MDAifQ","order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/85a46c3fe31041288a0a56c9","mcp":"traverse {\"id\":\"sb:e/85a46c3fe31041288a0a56c9\"}","page":"/entity/eli-lilly/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/85a46c3fe31041288a0a56c9\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/85a46c3fe31041288a0a56c9\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"free-record","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/85a46c3fe31041288a0a56c9\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"free-record","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/85a46c3fe31041288a0a56c9\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"free-record","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history, which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"free-record","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"free-record","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"watch","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"watch","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"watch","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"watch","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"one-time-read","reason":"one-time Reads are not offered through this door; use ask"}]}